Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051113 | 0.83 | TBXAS1 (0.51) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL6790618 | 0.82 | TBXAS1 (0.50) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL7279572 | 0.80 | TBXAS1 (0.49) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| Bicarbonate SCHEMBL29201334 | 0.79 | TBXAS1 (0.51) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL6550536 | 0.78 | TBXAS1 (0.51) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| Acetic Acid SCHEMBL8525552 | 0.78 | TBXAS1 (0.50) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL2523006 | 0.76 | — | — | |
| SCHEMBL6692416 | 0.76 | — | — | |
| SCHEMBL27909057 | 0.76 | TBXAS1 (0.49) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 | |
| SCHEMBL12928729 | 0.75 | TBXAS1 (0.51) | TBXAS1CYP11B1CYP11B2ALDH1A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024122393-A1 | COMPOSITION FOR IMPROVED STRAIGHTENING OF KERATIN FIBERS | L'OREAL (FR) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3615084-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200412-A1 | MEMBRANE ACTIVE MOLECULES | BraneQuest, Inc. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2018-10-25 | — | — | US | disclosed |
| EP-1212295-B1 | SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2008-10-01 | — | — | EP | disclosed |
| US-6495522-B1 | PREVENTING APOPTOTIC CELL DEATH IN WHICH THE LOSS OF CELLS, TISSUES OR ENTIRE ORGANS OCCURS | CYTOVIA, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1212295-A1 | SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016093-A1 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | TBXAS1 213/4885CYP11B1 884/4885CYP11B2 756/4885 |
| US-20180303821-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | TBXAS1 213/4885CYP11B1 884/4885CYP11B2 756/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | TBXAS1 213/4885CYP11B1 884/4885CYP11B2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.